TAKEDA PHARMACEUTICAL CO LTD
TAKThe Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".
Drugs in Pipeline
229
Phase 3 Programs
154
Upcoming Catalysts
12
Next Catalyst
This month
Market Overview
Stock performance and key metrics
15 upcoming, 3 past
TAK-360 Phase 2 Est. Readout
Primary completion for TAK-360 trial (NCT06812078) in Idiopathic Hypersomnia
Source14 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Epoetin
Chronic Kidney Disease
REPLAGAL
Fabry Disease
IGSC 20% infusion
Primary Immunodeficiency Disease
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
HYQVIA
Primary Immunodeficiency Diseases (PID)
Cyproterone acetate
Adenocarcinoma, Prostate
Escitalopram
Treatment Outcome
Maribavir
Cytomegalovirus (CMV)
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
Glimepiride
Diabetes Mellitus
TAK-816+ DPT-TAKEDA
Immunization
Lapaquistat acetate and lipid-lowering therapy
Type 2 Diabetes
Alectinib
ALK+ Advanced NSCLC
HAV Vaccine
Healthy Volunteers
Ramelteon
Sleep Initiation and Maintenance Disorders
TDV
Dengue Fever
Dexlansoprazole MR
Gastroesophageal Reflux Disease
Ixazomib
Multiple Myeloma
SYR-472
Diabetes Mellitus
Azilsartan medoxomil and hydrochlorothiazide
Essential Hypertension
TAK-583
Neuralgia, Postherpetic
Darvadstrocel
Crohn's Disease
Omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-536CCB
Grade I or II Essential Hypertension
Lansoprazole and naproxen and aspirin
Osteoarthritis
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Cancer
Pioglitazone and Metformin
Diabetes Mellitus
Idursulfase-IT
Hunter Syndrome
Lanadelumab
Angioedema
Vortioxetine tablets
Major Depressive Disorder
Leuprorelin
Prostatic Neoplasms
Resatorvid
Sepsis
Vedolizumab 300 mg IV
Colitis, Ulcerative
Vedolizumab SC 108 mg
Crohn's Disease
Alogliptin and glyburide
Diabetes Mellitus
SYR-322-MET
Clinical Pharmacology
TAK-438 10 mg
Non-erosive Gastroesophageal Reflux Disease
Vonicog Alfa
Von Willebrand Disease (VWD)
TAK-559
Diabetes Mellitus
Pantoprazole
Gastroesophageal Reflux Disease (GERD)
Mezagitamab
Immune Thrombocytopenic Purpura (ITP)
Active Comparator
Psoriatic Arthritis
Alogliptin and voglibose
Type 2 Diabetes Mellitus
Dexlansoprazole MR QD
Gastroesophageal Reflux
Deucravacitinib
Plaque Psoriasis
Azacitidine
Myelodysplastic Syndrome
von Willebrand factor (Recombinant)
Von Willebrand Disease
Azilsartan medoxomil and olmesartan
Hypertension
Lu AA21004
Major Depressive Disorder
TAK-536TCH tablet
Essential Hypertension
YF-17D
Dengue
Ixazomib Citrate
Multiple Myeloma
Lapaquistat acetate and simvastatin
Hypercholesterolemia
Upadacitinib
Crohn's Disease
MOVIPREP
Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
Velaglucerase Alfa
Gaucher Disease
Lapaquistat acetate and rosuvastatin
Hypercholesterolemia
High Dose Colchicine (4.8 mg total dose)
Gout
NE-58095 IR
Involutional Osteoporosis
Relugolix
Uterine Fibroids
Pioglitazone and Glimepiride
Diabetes Mellitus
Teduglutide
Short Bowel Syndrome
TVP-1012
Parkinson's Disease
Actovegin
Peripheral Arterial Diseases
TachoSil®
Hemorrhage
Febuxostat
Gout
Apremilast
Plaque Psoriasis
TAK-330
Coagulation Disorder
Voglibose
Type 2 Diabetes Mellitus
TAK-771
Primary Immunodeficiency Diseases (PID)
Surgicel® Original
Bleeding
TAP-144-SR(6M)
Prostate Cancer
Fasiglifam
Diabetes Mellitus, Type 2
Alogliptin Benzoate
Diabetes Mellitus, Type 2
Febuxostat IR
Gout
TVP-1012 1mg
Parkinson's Disease
Metformin HCl
Diabetes Mellitus
TAK-667
Hereditary Angioedema
Leuprorelin SR
Prostatic Neoplasms, Locally Advanced
VONVENDI
Von Willebrand Disease (VWD)
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Hypertension
Lapaquistat acetate and atorvastatin
Hypercholesterolemia
Glyburide
Diabetes Mellitus
Lapaquistat acetate and additional lipid-lowering therapy
Hypercholesterolemia
Vedolizumab
Colitis, Ulcerative
TAK-861
Narcolepsy Type 1
Azilsartan medoxomil and chlorthalidone
Essential Hypertension
Glipizide
Diabetes Mellitus
Vortioxetine
Major Depressive Disorder
TAK-881
Primary Immunodeficiency Diseases (PID)
TAK-536
Hypertension
Esomeprazole
Healthy Volunteers
Alogliptin and metformin
Type 2 Diabetes Mellitus
Parathyroid Hormone (PTH)
Osteoporosis
Lapaquistat Acetate
Dyslipidemia
Pioglitazone
Diabetes Mellitus
Allopurinol
Gout
Rapid-acting insulin secretagogue
Diabetes Mellitus
Candesartan
Heart Failure
Venticute
Pneumonia
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Alogliptin
Diabetes Mellitus, Type 2
Azilsartan medoxomil - chlorthalidone
Essential Hypertension
Azilsartan medoxomil
Essential Hypertension
Zasocitinib
Psoriatic Arthritis
TAK-019
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
TAK-438
Gastric Ulcers
Chlorthalidone
Hypertension
Adynovate
Hemophilia A
Bismuth-Containing Quadruple Therapy
Duodenal Ulcer
Azilsartan Medoxomil and amlodipine
Hypertension
Soticlestat
Dravet Syndrome (DS)
Lansoprazole
Esophagitis, Reflux
Vedolizumab IV
Moderately to Severely Active Ulcerative Colitis
Magnesium Pantoprazole
GERD
Rosiglitazone
Diabetes Mellitus
Bicalutamide
Prostate Cancer
TAK-279
Plaque Psoriasis
9vHPV Vaccine
Dengue Fever
Vonoprazan
Gastroesophageal Reflux
Zopiclone
Balance
Insulin
Diabetes Mellitus
Atorvastatin
Hypercholesterolemia
Elritercept
Myelodysplastic Syndromes
Dexlansoprazole
Gastroesophageal Reflux Disease
Olmesartan medoxomil-hydrochlorothiazide
Essential Hypertension
Ramipril
Hypertension
Valsartan
Hypertension
Simvastatin
Hypercholesterolemia
Amoxicillin
H. Pylori Infection
TAK-672
Acquired Hemophilia A
Adalimumab
Colitis, Ulcerative
Vedolizumab SC
Ulcerative Colitis
Lubiprostone
Constipation
Gefarnate
Stomach Ulcer
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Intranasal Fentanyl Spray (INFS)
Break Through Pain
TVP-1012 0.5mg
Parkinson's Disease
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Dengue Fever
Metformin hydrochloride
Type 2 Diabetes Mellitus
Azilsartan
Hypertension
Olmesartan medoxomil and hydrochlorothiazide
Essential Hypertension
Lansoprazole microgranules suspension
Gastroesophageal Reflux Disease
Concomitant Antibiotic Therapy
Pouchitis
Metformin
Type 2 Diabetes Mellitus
Duloxetine
Major Depressive Disorder
TAK-743 300 mg
Hereditary Angioedema
Cyclobenzaprine HCl
Neck Pain
TAK-625
Alagille Syndrome (ALGS)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
TAK-875
Diabetes Mellitus
TAK-003
Dengue Fever
TAK-816
Healthy Volunteers
Brigatinib
ALK-positive Advanced NSCLC
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
Dengue Fever
Leuprorelin acetate
Endometriosis
Pioglitazone and azilsartan
Diabetes Mellitus
TAK-662
Congenital Protein C Deficiency
TAK-101
Celiac Disease
TAK-850
Influenza Infection
GDX012
Leukemia
Dazostinag
Solid Neoplasms
Pioglitazone and atorvastatin
Cardiovascular Diseases
Zasocitinib (Dose A)
Hidradenitis Suppurativa
Norwalk VLP vaccine
Acute Gastroenteritis
TAK-919
Coronavirus Disease (COVID-19)
TAK-188
Advanced or Metastatic Solid Tumors
Levothyroxine sodium new formulation
Hypothyroidism
TD-8954
Enteral Feeding Intolerance
NoV Vaccine
Healthy Volunteers
Peginesatide
Anemia
Ramelteon and gabapentin
Sleep Initiation and Maintenance Disorders
TAK-981
Advanced or Metastatic Solid Tumors
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Dengue Fever
TAK-935
Developmental and/or Epileptic Encephalopathies
TAK-341
Multiple System Atrophy
Hepatitis A Vaccine
Healthy Volunteers
TAK-954
Postoperative Gastrointestinal Dysfunction
TAK-079
Primary Immune Thrombocytopenia
Norovirus Bivalent VLP Vaccine
Norovirus Prevention
TAK-063 20 mg
Schizophrenia
MCC-135
Congestive Heart Failure
NoV GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
Brentuximab Vedotin
Lymphoma
TAK-715 and methotrexate
Arthritis, Rheumatoid
TAK-007
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Daratumumab
Multiple Myeloma
Ruxolitinib
Myelofibrosis
TAK-272
Type 2 Diabetes Mellitus and Microalbuminuria
TAK-783 and methotrexate
Arthritis, Rheumatoid
TAK-442
Acute Coronary Syndrome
Ponatinib
Myeloid Leukemia, Chronic, Chronic Phase
Norovirus Bivalent Vaccine
Prevention From Norovirus Infection
vortioxetine (Lu AA21004)
Depressive Disorder, Major
Sitagliptin
Diabetes Mellitus
Panitumumab + TAS-102
Colorectal Cancer
TAK-360
Idiopathic Hypersomnia
TAK-853
Ovarian Cancer
Pevonedistat
Acute Myeloid Leukemia (AML)
Doxorubicin
Hodgkin Disease
GI.1/GII.4 (15/15)
Norovirus
TAK-411
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NDI-034858
Psoriatic Arthritis
TAK-062
Celiac Disease
TAK-071
Parkinson Disease
Leuprorelin (GF)
Uterine Fibroids
Pioglitazone and insulin
Diabetes Mellitus
Olmesartan
Hypertension
TAK-951
Postoperative Nausea and Vomiting (PONV)
Candesartan cilexetil
Essential Hypertension
Ramelteon and doxepin
Sleep Initiation and Maintenance Disorders
TAK-850 0.5 mL injection
Influenza Infection
Cabozantinib
Advanced Renal Cell Carcinoma
TIMP-GLIA
Celiac Disease
Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
NDI-034858 study drug
Moderate to Severe Plaque Psoriasis
Namilumab
Rheumatoid Arthritis
Lapaquistat acetate and fenofibrate
Hyperlipidemias
Subcutaneous injection of TAK-850
Influenza Infection
Ilaprazole
Esophagitis
TAK-861 2 mg
Narcolepsy Type 2
TAK-128
Diabetic Neuropathies
TAK-788
Carcinoma, Non-Small-Cell Lung
Lenalidomide
Relapsed and/or Refractory Multiple Myeloma
TDV Liquid Formulation 1
Dengue Fever
TAK-385
Uterine Fibroids
Niraparib
Ovarian Cancer
Enoxaparin
Venous Thromboembolism
Pioglitazone and ramipril
Inflammation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epoetin | Phase 3 | Chronic Kidney Disease | - | - |
REPLAGAL | Phase 3 | Fabry Disease | - | - |
IGSC 20% infusion | Phase 3 | Primary Immunodeficiency Disease | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
HYQVIA | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Cyproterone acetate | Phase 3 | Adenocarcinoma, Prostate | - | - |
Escitalopram | Phase 3 | Treatment Outcome | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
Glimepiride | Phase 3 | Diabetes Mellitus | - | - |
TAK-816+ DPT-TAKEDA | Phase 3 | Immunization | - | - |
Lapaquistat acetate and lipid-lowering therapy | Phase 3 | Type 2 Diabetes | - | - |
Alectinib | Phase 3 | ALK+ Advanced NSCLC | - | - |
HAV Vaccine | Phase 3 | Healthy Volunteers | - | - |
Ramelteon | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
TDV | Phase 3 | Dengue Fever | - | - |
Dexlansoprazole MR | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
SYR-472 | Phase 3 | Diabetes Mellitus | - | - |
Azilsartan medoxomil and hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
TAK-583 | Phase 3 | Neuralgia, Postherpetic | - | - |
Darvadstrocel | Phase 3 | Crohn's Disease | - | - |
Omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-536CCB | Phase 3 | Grade I or II Essential Hypertension | - | - |
Lansoprazole and naproxen and aspirin | Phase 3 | Osteoarthritis | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 3 | Colorectal Cancer | - | - |
Pioglitazone and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Idursulfase-IT | Phase 3 | Hunter Syndrome | - | - |
Lanadelumab | Phase 3 | Angioedema | - | - |
Vortioxetine tablets | Phase 3 | Major Depressive Disorder | - | - |
Leuprorelin | Phase 3 | Prostatic Neoplasms | - | - |
Resatorvid | Phase 3 | Sepsis | - | - |
Vedolizumab 300 mg IV | Phase 3 | Colitis, Ulcerative | - | - |
Vedolizumab SC 108 mg | Phase 3 | Crohn's Disease | - | - |
Alogliptin and glyburide | Phase 3 | Diabetes Mellitus | - | - |
SYR-322-MET | Phase 3 | Clinical Pharmacology | - | - |
TAK-438 10 mg | Phase 3 | Non-erosive Gastroesophageal Reflux Disease | - | - |
Vonicog Alfa | Phase 3 | Von Willebrand Disease (VWD) | - | - |
TAK-559 | Phase 3 | Diabetes Mellitus | - | - |
Pantoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Mezagitamab | Phase 3 | Immune Thrombocytopenic Purpura (ITP) | - | - |
Active Comparator | Phase 3 | Psoriatic Arthritis | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR QD | Phase 3 | Gastroesophageal Reflux | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Azacitidine | Phase 3 | Myelodysplastic Syndrome | - | - |
von Willebrand factor (Recombinant) | Phase 3 | Von Willebrand Disease | - | - |
Azilsartan medoxomil and olmesartan | Phase 3 | Hypertension | - | - |
Lu AA21004 | Phase 3 | Major Depressive Disorder | - | - |
TAK-536TCH tablet | Phase 3 | Essential Hypertension | - | - |
YF-17D | Phase 3 | Dengue | - | - |
Ixazomib Citrate | Phase 3 | Multiple Myeloma | - | - |
Lapaquistat acetate and simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Upadacitinib | Phase 3 | Crohn's Disease | - | - |
MOVIPREP | Phase 3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | - | - |
Velaglucerase Alfa | Phase 3 | Gaucher Disease | - | - |
Lapaquistat acetate and rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
High Dose Colchicine (4.8 mg total dose) | Phase 3 | Gout | - | - |
NE-58095 IR | Phase 3 | Involutional Osteoporosis | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Pioglitazone and Glimepiride | Phase 3 | Diabetes Mellitus | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
TVP-1012 | Phase 3 | Parkinson's Disease | - | - |
Actovegin | Phase 3 | Peripheral Arterial Diseases | - | - |
TachoSil® | Phase 3 | Hemorrhage | - | - |
Febuxostat | Phase 3 | Gout | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
TAK-330 | Phase 3 | Coagulation Disorder | - | - |
Voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TAK-771 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Surgicel® Original | Phase 3 | Bleeding | - | - |
TAP-144-SR(6M) | Phase 3 | Prostate Cancer | - | - |
Fasiglifam | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Alogliptin Benzoate | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
Metformin HCl | Phase 3 | Diabetes Mellitus | - | - |
TAK-667 | Phase 3 | Hereditary Angioedema | - | - |
Leuprorelin SR | Phase 3 | Prostatic Neoplasms, Locally Advanced | - | - |
VONVENDI | Phase 3 | Von Willebrand Disease (VWD) | - | - |
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. | Phase 3 | Hypertension | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Glyburide | Phase 3 | Diabetes Mellitus | - | - |
Lapaquistat acetate and additional lipid-lowering therapy | Phase 3 | Hypercholesterolemia | - | - |
Vedolizumab | Phase 3 | Colitis, Ulcerative | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Glipizide | Phase 3 | Diabetes Mellitus | - | - |
Vortioxetine | Phase 3 | Major Depressive Disorder | - | - |
TAK-881 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
TAK-536 | Phase 3 | Hypertension | - | - |
Esomeprazole | Phase 3 | Healthy Volunteers | - | - |
Alogliptin and metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Parathyroid Hormone (PTH) | Phase 3 | Osteoporosis | - | - |
Lapaquistat Acetate | Phase 3 | Dyslipidemia | - | - |
Pioglitazone | Phase 3 | Diabetes Mellitus | - | - |
Allopurinol | Phase 3 | Gout | - | - |
Rapid-acting insulin secretagogue | Phase 3 | Diabetes Mellitus | - | - |
Candesartan | Phase 3 | Heart Failure | - | - |
Venticute | Phase 3 | Pneumonia | - | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Alogliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Azilsartan medoxomil - chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Azilsartan medoxomil | Phase 3 | Essential Hypertension | - | - |
Zasocitinib | Phase 3 | Psoriatic Arthritis | - | - |
TAK-019 | Phase 3 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | - | - |
TAK-438 | Phase 3 | Gastric Ulcers | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Adynovate | Phase 3 | Hemophilia A | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Duodenal Ulcer | - | - |
Azilsartan Medoxomil and amlodipine | Phase 3 | Hypertension | - | - |
Soticlestat | Phase 3 | Dravet Syndrome (DS) | - | - |
Lansoprazole | Phase 3 | Esophagitis, Reflux | - | - |
Vedolizumab IV | Phase 3 | Moderately to Severely Active Ulcerative Colitis | - | - |
Magnesium Pantoprazole | Phase 3 | GERD | - | - |
Rosiglitazone | Phase 3 | Diabetes Mellitus | - | - |
Bicalutamide | Phase 3 | Prostate Cancer | - | - |
TAK-279 | Phase 3 | Plaque Psoriasis | - | - |
9vHPV Vaccine | Phase 3 | Dengue Fever | - | - |
Vonoprazan | Phase 3 | Gastroesophageal Reflux | - | - |
Zopiclone | Phase 3 | Balance | - | - |
Insulin | Phase 3 | Diabetes Mellitus | - | - |
Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Olmesartan medoxomil-hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Ramipril | Phase 3 | Hypertension | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Amoxicillin | Phase 3 | H. Pylori Infection | - | - |
TAK-672 | Phase 3 | Acquired Hemophilia A | - | - |
Adalimumab | Phase 3 | Colitis, Ulcerative | - | - |
Vedolizumab SC | Phase 3 | Ulcerative Colitis | - | - |
Lubiprostone | Phase 3 | Constipation | - | - |
Gefarnate | Phase 3 | Stomach Ulcer | - | - |
TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
Intranasal Fentanyl Spray (INFS) | Phase 3 | Break Through Pain | - | - |
TVP-1012 0.5mg | Phase 3 | Parkinson's Disease | - | - |
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) | Phase 3 | Dengue Fever | - | - |
Metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Azilsartan | Phase 3 | Hypertension | - | - |
Olmesartan medoxomil and hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
Lansoprazole microgranules suspension | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Concomitant Antibiotic Therapy | Phase 3 | Pouchitis | - | - |
Metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Duloxetine | Phase 3 | Major Depressive Disorder | - | - |
TAK-743 300 mg | Phase 3 | Hereditary Angioedema | - | - |
Cyclobenzaprine HCl | Phase 3 | Neck Pain | - | - |
TAK-625 | Phase 3 | Alagille Syndrome (ALGS) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
TAK-003 | Phase 3 | Dengue Fever | - | - |
TAK-816 | Phase 3 | Healthy Volunteers | - | - |
Brigatinib | Phase 3 | ALK-positive Advanced NSCLC | - | - |
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Phase 2 | Dengue Fever | - | - |
Leuprorelin acetate | Phase 2 | Endometriosis | - | - |
Pioglitazone and azilsartan | Phase 2 | Diabetes Mellitus | - | - |
TAK-662 | Phase 2 | Congenital Protein C Deficiency | - | - |
TAK-101 | Phase 2 | Celiac Disease | - | - |
TAK-850 | Phase 2 | Influenza Infection | - | - |
GDX012 | Phase 2 | Leukemia | - | - |
Dazostinag | Phase 2 | Solid Neoplasms | - | - |
Pioglitazone and atorvastatin | Phase 2 | Cardiovascular Diseases | - | - |
Zasocitinib (Dose A) | Phase 2 | Hidradenitis Suppurativa | - | - |
Norwalk VLP vaccine | Phase 2 | Acute Gastroenteritis | - | - |
TAK-919 | Phase 2 | Coronavirus Disease (COVID-19) | - | - |
TAK-188 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Levothyroxine sodium new formulation | Phase 2 | Hypothyroidism | - | - |
TD-8954 | Phase 2 | Enteral Feeding Intolerance | - | - |
NoV Vaccine | Phase 2 | Healthy Volunteers | - | - |
Peginesatide | Phase 2 | Anemia | - | - |
Ramelteon and gabapentin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
TAK-981 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Phase 2 | Dengue Fever | - | - |
TAK-935 | Phase 2 | Developmental and/or Epileptic Encephalopathies | - | - |
TAK-341 | Phase 2 | Multiple System Atrophy | - | - |
Hepatitis A Vaccine | Phase 2 | Healthy Volunteers | - | - |
TAK-954 | Phase 2 | Postoperative Gastrointestinal Dysfunction | - | - |
TAK-079 | Phase 2 | Primary Immune Thrombocytopenia | - | - |
Norovirus Bivalent VLP Vaccine | Phase 2 | Norovirus Prevention | - | - |
TAK-063 20 mg | Phase 2 | Schizophrenia | - | - |
MCC-135 | Phase 2 | Congestive Heart Failure | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
Brentuximab Vedotin | Phase 2 | Lymphoma | - | - |
TAK-715 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
TAK-007 | Phase 2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | - | - |
Daratumumab | Phase 2 | Multiple Myeloma | - | - |
Ruxolitinib | Phase 2 | Myelofibrosis | - | - |
TAK-272 | Phase 2 | Type 2 Diabetes Mellitus and Microalbuminuria | - | - |
TAK-783 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
TAK-442 | Phase 2 | Acute Coronary Syndrome | - | - |
Ponatinib | Phase 2 | Myeloid Leukemia, Chronic, Chronic Phase | - | - |
Norovirus Bivalent Vaccine | Phase 2 | Prevention From Norovirus Infection | - | - |
vortioxetine (Lu AA21004) | Phase 2 | Depressive Disorder, Major | - | - |
Sitagliptin | Phase 2 | Diabetes Mellitus | - | - |
Panitumumab + TAS-102 | Phase 2 | Colorectal Cancer | - | - |
TAK-360 | Phase 2 | Idiopathic Hypersomnia | - | - |
TAK-853 | Phase 2 | Ovarian Cancer | - | - |
Pevonedistat | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Doxorubicin | Phase 2 | Hodgkin Disease | - | - |
GI.1/GII.4 (15/15) | Phase 2 | Norovirus | - | - |
TAK-411 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
NDI-034858 | Phase 2 | Psoriatic Arthritis | - | - |
TAK-062 | Phase 2 | Celiac Disease | - | - |
TAK-071 | Phase 2 | Parkinson Disease | - | - |
Leuprorelin (GF) | Phase 2 | Uterine Fibroids | - | - |
Pioglitazone and insulin | Phase 2 | Diabetes Mellitus | - | - |
Olmesartan | Phase 2 | Hypertension | - | - |
TAK-951 | Phase 2 | Postoperative Nausea and Vomiting (PONV) | - | - |
Candesartan cilexetil | Phase 2 | Essential Hypertension | - | - |
Ramelteon and doxepin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
TAK-850 0.5 mL injection | Phase 2 | Influenza Infection | - | - |
Cabozantinib | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
TIMP-GLIA | Phase 2 | Celiac Disease | - | - |
Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
NDI-034858 study drug | Phase 2 | Moderate to Severe Plaque Psoriasis | - | - |
Namilumab | Phase 2 | Rheumatoid Arthritis | - | - |
Lapaquistat acetate and fenofibrate | Phase 2 | Hyperlipidemias | - | - |
Subcutaneous injection of TAK-850 | Phase 2 | Influenza Infection | - | - |
Ilaprazole | Phase 2 | Esophagitis | - | - |
TAK-861 2 mg | Phase 2 | Narcolepsy Type 2 | - | - |
TAK-128 | Phase 2 | Diabetic Neuropathies | - | - |
TAK-788 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Lenalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
TDV Liquid Formulation 1 | Phase 2 | Dengue Fever | - | - |
TAK-385 | Phase 2 | Uterine Fibroids | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
Enoxaparin | Phase 2 | Venous Thromboembolism | - | - |
Pioglitazone and ramipril | Phase 2 | Inflammation | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 229 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TAK) pipeline across Phase 3, Phase 2. Its lead program is Epoetin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TAK) next tracked catalyst is a Phase 2 expected July 16, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TAK biotech catalysts?→
Add TAK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.